Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1196-1203

  Bond, Jennifer E ^a   Bergeron, Andrew ^a   Thurlow, Peter ^a   Angelica Selim, M ^a   Bowers, Edith V ^a   Kuang, Anna ^b   Levinson, Howard ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN II; ANGIOTENSIN II RECEPTOR 2; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN RECEPTOR; BLEBBISTATIN; EMD 66684; LOSARTAN; MYOSIN II; NONMUSCLE MYOSIN II; NONMUSCLE MYOSIN IIA; NONMUSCLE MYOSIN IIB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KELOID; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANGIOTENSIN II; CELL MOVEMENT; CELL PROLIFERATION; DERMIS; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; MALE; MIDDLE AGED; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; NONMUSCLE MYOSIN TYPE IIB; PROTEIN ISOFORMS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; YOUNG ADULT;

EID: 82855172196     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00265     Document Type: Article

References (45)

1. Butler PD, Longaker MT, Yang GP. (2008) Current progress in keloid research and treatment. J. Am. Coll. Surg. 206:731-41.
2. Lee JY, Yang CC, Chao SC, Wong TW. (2004) Histopathological differential diagnosis of keloid and hypertrophic scar. Am. J. Dermatopathol. 26:379-84.
3. Tuan TL, Nichter LS. (1998) The molecular basis of keloid and hypertrophic scar formation. Mol. Med. Today. 4:19-24.
4. Atiyeh BS, Costagliola M, Hayek SN. (2005) Keloid or hypertrophic scar: the controversy: review of the literature. Ann. Plast. Surg. 54:676-80.
5. Witt E, Maliri A, McGrouther DA, Bayat A. (2008) RAC activity in keloid disease: comparative analysis of fibroblasts from margin of keloid to its surrounding normal skin. Eplasty. 8:e19.
6. Lim CP, Phan TT, Lim IJ, Cao X. (2006) Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene. 25:5416-25.
7. Haisa M, Okochi H, Grotendorst GR. (1994) Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J. Invest. Dermatol. 103:560-3.
8. Yoshimoto H, et al. (1999) Overexpression of insulin- like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am. J. Pathol. 154:883-9.
9. Fujiwara M, Muragaki Y, Ooshima A. (2005) Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br. J. Dermatol. 153:295-300.
10. Murray JC. (1994) Keloids and hypertrophic scars. Clin. Dermatol. 12:27-37.
11. Dzau VJ. (1988) Circulating versus local reninangiotensin system in cardiovascular homeostasis. Circulation. 77:I4-13.
12. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52:415-72.
13. Kim S, Iwao H. (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52:11-34.
14. Steckelings UM, et al. (2004) Human skin: source of and target organ for angiotensin II. Exp. Dermatol. 13:148-54.
15. Steckelings UM, Henz BM, Wiehstutz S, Unger T, Artuc M. (2005) Differential expression of angiotensin receptors in human cutaneous wound healing. Br. J. Dermatol. 153:887-93.
16. Morihara K, et al. (2006) Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin. J. Am. Acad. Dermatol. 54:251-7.
17. 1) angiotensin II receptors provided by gene targeting. Trends Endocrinol. Metab. 11:263-9.
18. 2 receptors: regulation, signalling and function. Blood Press. 12:70-88.
19. Nickenig G, Geisen G, Vetter H, Sachinidis A. (1997) Characterization of angiotensin receptors on human skin fibroblasts. J. Mol. Med. 75:217-22.
20. Kawaguchi Y, Kamatani N. (2002) Contribution of angiotensin II type I and type II receptors(AT-1 and AT-2) to collagen synthesis by skin fibroblasts [in Japanese]. Nippon Rinsho. 60:1940-4.
21. Kawaguchi Y, et al. (2004) Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum. 50:216-26.
22. Yahata Y, et al. (2006) A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J. Biol. Chem. 281:13209-16.
23. Rodgers KE, et al. (2005) Fragments of Nleangiotensin(1-7) accelerate healing in dermal models. J. Pept. Res. 66 Suppl 1:41-47.
24. Rodgers KE, et al. (2003) Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast. Reconstr. Surg. 111:1195-206.
25. Cai Y, et al. (2006) Nonmuscle myosin IIAdependent force inhibits cell spreading and drives F-actin flow. Biophys. J. 91:3907-20.
26. Conti MA, Adelstein RS. (2008) Nonmuscle myosin II moves in new directions. J. Cell Sci. 121:11-8.
27. Ridley AJ, et al. (2003) Cell migration: integrating signals from front to back. Science. 302:1704-1709.
28. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. (2009) Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell. Biol. 10:778-90.
29. Birnbaum S, et al. (2009) Further evidence for the involvement of MYH9 in the etiology of nonsyndromic cleft lip with or without cleft palate. Eur. J. Oral Sci. 117:200-3.
30. Even-Ram S, et al. (2007) Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk. Nat. Cell. Biol 9:299-309.
31. Kim S, Iwao H. (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52:11-34.
32. Mederski WW, et al. (1994) Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro- 4-oxo-3H-imidazo[4,5-c]pyridine derivatives. J. Med. Chem. 37:1632-45.
33. Timmermans PB, et al. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45:205-51.
34. Matsubara H. (1998) Pathophysiological role of angiotensin II Type 2 receptor in cardiovascular and renal diseases. Circ. Res. 83:1182-91.
35. Matsubara H, et al. (1994) Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. J. Clin. Invest. 93:1592-601.
36. Villar-Cheda B, et al. (2010) Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson′s disease. Eur. J. Neurosci. 32:1695-706.
37. Sasamura H, et al. (1997) Regulation of vascular type 1 angiotensin receptors by cytokines. Hypertension. 30:35-41.
38. Rodgers K, et al. (2001) Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen. 9:238-47.
39. Sun Y, Ramires FJ, Zhou G, Ganjam VK, Weber KT. (1997) Fibrous tissue and angiotensin II. J. Mol. Cell. Cardiol. 29:2001-12.
40. Sun Y. (1997) Local angiotensin II and myocardial fibrosis. Adv. Exp. Med. Biol. 432:55-61.
41. 1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol. 302:237-43.
42. Moen MD, Wagstaff AJ. (2005) Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs. 65:2657-74.
43. Birkenhager WH, de Leeuw PW. (1999) Nonpeptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J. Hypertens. 17:873-81.
44. Atzori L, Pinna AL, Ferreli C, Aste N. (2006) Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drugsurveillance center. Dermatol. Online. J. 12:1.
45. Femiano F. (2003) [Mucocutaneous bullous pemphigoid induced by valsartan. A clinical case]. Minerva Stomatol. 52:187-90.